RSV Seasonal Vaccine Introduction and Growth Strategy
68 assets in clinical development: upcoming pipeline catalysts
H2 2023
Regulatory decision
Arexvy RSV, ≥60 YOA (JP)
cabotegravir (long-acting), pre-exposure (EU)
Vocabria, HIV treatment (CN)
H1 2024
momelotinib MOMENTUM, myelofibrosis (EU, JP)
Jemperli RUBY IL DMMR/MSI-H endometrial cancer
(EU)
H2 2024
Arexvy, RSV, 50-59 YOA (US, EU, JP)
gepotidacin EAGLE-2/3, uUTI (US, EU)
Nucala, nasal polyposis (JP)
Nucala, severe asthma (CN)
Regulatory submission
and acceptance
momelotinib MOMENTUM, myelofibrosis (US)
Jemperli RUBY, 1L dMMR/MSI-H endometrial cancer
(US)
Arexvy, RSV, 50-59 YOA (US, EU, JP)
gepotidacin EAGLE-2/3, uUTI (US, EU)
Nucala, nasal polyposis (CN, JP)
momelotinib MOMENTUM, myelofibrosis (JP)
MenABCWY vaccine 1st generation (US, EU)
Jemperli RUBY Part 2, 1L endometrial cancer (US, EU)
Blenrep DREAMM-7/8, 2L+ multiple myeloma (US, EU)
gepotidacin EAGLE-1, GC (US)
Nucala MATINEE, COPD (US)
Phase III
Arexvy, RSV, 50-59 YoA
Blenrep DREAMM-7/8, 2L+ multiple myeloma
gepotidacin EAGLE-1, GC
Zejula FIRST IL maintenance ovarian cancer
Jemperli RUBY Part 2, 1L endometrial cancer
Nucala MATINEE, COPD
depemokimab SWIFT-1/2, asthma
depemokimab ANCHOR-1/2, CRSWNP
Zejula ZEAL, IL maintenance NSCLC
cobolimab COSTAR, 2L NSCLC
linerixibat GLISTEN, cholestatic pruritus in PBC
Targeted Business Development
Select phase II, phase I, and
investment decisions
bepirovirsen B-TOGETHER, HBV
mRNA Seasonal Flu
GSK3858279 CCL17, Diabetic Neuropathic pain, OA pain
GSK1070806 IL18, atopic dermatitis
GSK3943104, Herpes Simplex Virus
Cabotegravir + N6LS
VH4524184 HIV integrase inhibitor (LA)
VH3739937 HIV maturation inhibitor
VH4004280 HIV-1 capsid protein inhibitor (LA and oral)
MenABCWY vaccine 2nd generation
mRNA COVID-19
GSK4428859 anti-TIGIT
VH4524184 HIV integrase inhibitor (LA)
GSK
mRNA Seasonal flu/COVID-19
Infectious Diseases
Respiratory/Immunology
Opportunity driven
HIV
Oncology
12View entire presentation